[Innovative treatment of acute migraine pain with CGRP receptor antagonists].
Neurogenic inflammation caused by the release of vasoactive neuropeptides such as calcitonin gene-related peptide (CGRP) from nociceptive perivascular nerve fibres has been implicated in the development of acute migraine pain. It has recently been demonstrated that the CGRP receptor antagonist BIBN 4096 BS significantly reduces acute pain in migraine. This therapeutic efficacy provides further evidence for a critical role of CGRP in the pathophysiology of migraine. Given the apparent absence of vasoconstrictor activity both in meningeal and extracranial vessels, BIBN 4096 BS may provide an alternative for the treatment of migraine in those patients where triptans and ergotamine derivatives are contraindicated due to their side effects.
Herbert
M K
MK
Klinik und Poliklinik für Anästhesiologie der Universität Würzburg. herbert_m@klinik.uni-wuerzburg.de
Holzer
P
P
D015740:Calcitonin Gene-Related Peptide / Q000031:analogs & derivatives*; D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000077221:Calcitonin Gene-Related Peptide Receptor Antagonists; D010879:Piperazines; D011799:Quinazolines; D014665:Vasodilator Agents; D015740:Calcitonin Gene-Related Peptide; C406305:olcegepant